Cla Siegall is Changing Cancer Treatment at Seattle Genetics

Founded in 1998, Seattle Genetics boasts being the largest biotech company in Washington state. Seattle Genetics has 900 employees and a market value that is just shy of $10 million. There is a good chance that 200 more employees will be hired within the next year. Seattle Genetics has been studying human antibodies and has had some success in utilizing them to develop drugs that can treat cancers and other diseases. Their flagship drug, Adcetris, is still being studied but is believed to be able to cure Hodgkin Lymphoma, which is known for its high fatality rate due to the speed which it invades other organs. While it has been FDA approved, Adcetris is still a third tier drug for doctors in the fight against Hodgkin Lymphoma. The company is sure it will become the number one choice as time goes on.

The company’s incredible success is obvious when you look at the numbers. Sales from 2014 to 2016 increased by 46%. This is because their drugs are being found to be highly effective. Their drugs target the antigens in our bodies. Antigens are protein molecules which cause the production of antibodies within the immune system. These antigens attach to the outside of cells from diseases or cancer and kill the cells. This is a huge improvement over current radiation and chemotherapy because both radiation and chemotherapy cannot just target bad cells, they must also target healthy cells.

Clay Siegall, co-founder, and CEO of Seattle Genetics has high hopes for his company’s success. He dreams of Seattle becoming the place for top doctors to come and do their research. Mr. Siegall received a bachelor’s degree in zoology from the University of Maryland. He then went on to get a Ph.D. in genetics from George Washington University. In 2012 he won Pacific Northwest Ernst & Young’s Entrepreneur of the Year award. In 2013 the University of Maryland recognized Mr. Siegall as Alumnus of the Year for Computer, Math and Natural Sciences.

In addition to being CEO of Seattle Genetics, Clay Siegall sits on the board of directors for Ultragenyx Pharmaceutical, Mirna Therapeutics, and Alder Biopharmaceuticals Inc. Mr. Siegall has taken his education in the sciences and used it to grow a pharmaceutical company which is looking at cures for cancer in a completely new way. Seattle Genetics, with Clay Siegall at the helm, will change the world.

Leave a Reply

Your email address will not be published. Required fields are marked *